The central parity of RMB against the US dollar was reported at 7.1876, down by 22 points; The median price of the previous trading day was 7.1854, the official closing price of the previous trading day was 7.2630, and it closed at 7.2700 last night.The three major indexes all fell by more than 1%, with nearly 4,200 stocks, and the index weakened sharply. The Shanghai Composite Index fell by more than 1%, the Shenzhen Component Index fell by 1.24%, and the Growth Enterprise Market Index fell by 1.45%. Securities, real estate and photovoltaics were among the top losers, with nearly 4,200 stocks falling in Shanghai, Shenzhen and Beijing.Hong Kong stock Jingtai Holdings plunged nearly 15%, and the company's 1.464 million restricted shares are expected to circulate freely from today.
Hong Kong stock Jingtai Holdings plunged nearly 15%, and the company's 1.464 million restricted shares are expected to circulate freely from today.The central bank's open market today launched a 7-day reverse repurchase operation of 205.1 billion yuan, and the operating interest rate was flat at 1.50%. Today, 190.9 billion yuan of 7-day reverse repurchase expired, and the net investment on that day was 14.2 billion yuan.Most gold stocks in Hong Kong stocks fell, and Lingbao Gold fell by nearly 5%. As of press time, Lingbao Gold (03330.HK) fell by 4.75%, Zijin Mining (02899.HK) fell by 2.82% and Zhaojin Mining (01818.HK) fell by 2.75%.
The 28th meeting of the China-ROK Joint Economic and Trade Commission was held in Seoul, South Korea. On the 12th, Vice Minister of Commerce Li Fei co-chaired the 28th meeting of the China-ROK Joint Economic and Trade Commission with Vice Minister of Foreign Affairs Jiang Renxian in Seoul, South Korea. The two sides exchanged views on deepening China-ROK industrial chain supply chain, trade and investment, regional and multilateral cooperation, pragmatically promoted related matters, and reached broad consensus.Hebai Group: With the help of policy dividends, it will further stimulate new consumer demand and help the company's sales promotion. Hebai Group (000417) said on the interactive platform on December 13th that the company's top 100 electrical appliances actively grasped the new round of "trade-in" policy opportunity, adhered to "policy+activity" to stimulate new consumption potential, and quickly launched more than 33,000 subsidized goods in 8 categories of household appliances and 24 categories of smart homes. Since the implementation of the national subsidy policy in 2024, there have been more than 100,000 rejuvenation machines in stores in Anhui Province, with sales exceeding 400 million yuan, and the sales of household appliances in stores increased by 121% year-on-year. In the next step, the company will seize the time window, continue to integrate resources, closely focus on the national subsidy policy for household appliances in Anhui Province and Hefei consumer vouchers, and further stimulate new consumer demand with the help of policy dividends to help the company's sales increase.Shanghai Securities: The pharmaceutical and bio-industry is expected to further repair its performance and valuation. The Shanghai Securities Research Report pointed out that with the support of policies and the adjustment of the internal structure of the industry, the pharmaceutical and bio-industry is expected to further repair its performance and valuation. It is suggested to pay attention to five directions: 1) Innovative drugs (with strong national policy support, the payment terminal is expected to further improve and go to sea to occupy the global market); 2)CXO (the negative impact of the biosafety bill event has been eliminated, and the demand for orders in the superimposed interest rate reduction cycle has increased, which is expected to usher in a double repair of performance and valuation); 3) Imitation and innovation (centralized procurement is expected to clear up, increase innovation, and traditional pharmaceutical companies will usher in new opportunities); 4) Traditional Chinese Medicine (the national policy supports the innovation of traditional Chinese medicine, and its performance is expected to maintain a good growth rate); 5) Medical devices (equipment updating, high-consumption innovation, low-consumption going to sea, etc.). Individual stocks can be concerned about: Baekje Shenzhou, Wuxi PharmaTech, China Resources Sanjiu and so on.
Strategy guide 12-14
Strategy guide
Strategy guide
12-14